Our researchers and physicians will be joining colleagues from around the world at the American Society of Clinical Oncology’s 2024 annual meeting in Chicago. This year’s theme is the Art and Science of Cancer Care: From Comfort to Cure. View full conference information and abstract titles.

During this year’s meeting, Jeffrey S. Weber, MD, PhD will be presenting late-breaking data on a phase 2 trial exploring the effectiveness of combining the immunotherapy drug pembrolizumab with the neoantigen mRNA vaccine V940 for people with high-risk, surgically removed melanoma.

Below are notable sessions featuring our faculty and trainees this year (see full listings of presenters at the links provided).

Saturday, June 1

Poster
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM)
Session: Central Nervous System Tumors
NYU Langone Presenter: Dimitris G. Placantonakis, MD, PhD
Time: 9:00AM–12:00PM

Poster
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH)
Session: Developmental Therapeutics–Immunotherapy
NYU Langone Presenter: Salman R. Punekar, MD
NYU Langone Authors: Leslie R. Boyd, MD
Time: 9:00AM–12:00PM

Poster
An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation
Session: Developmental Therapeutics–Immunotherapy
NYU Langone Presenter: Salman R. Punekar, MD
Time: 9:00AM–12:00PM

Poster
Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma
Session: Melanoma/Skin Cancers
NYU Langone Presenter: Jeffrey S. Weber, MD, PhD
NYU Langone Authors: Judith D. Goldberg, ScD, Janice Mehnert, MD, Xiaochun Li, Benjamin Levinson
Time: 1:30–4:30PM

Poster
INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma
Session: Melanoma/Skin Cancers
NYU Langone Presenter: Jeffrey S. Weber, MD, PhD
Time: 1:30–4:30PM

Monday, June 3

Late-Breaking Data
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial
A follow-up presentation to the recently published clinical trial describing the effectiveness of combining the immunotherapy drug pembrolizumab with the neoantigen mRNA vaccine V940. This three-year update shows a higher percentage of durable and meaningful long-term recurrence-free survival or survival without distant spread of cancer in patients who received both treatments (74.8%) compared to those who received only pembrolizumab (55.6%).
Session: Melanoma/Skin Cancers
NYU Langone Presenter: Jeffrey S. Weber, MD, PhD
Time: 10:15–10:21AM

Poster
Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023
Session: Gynecologic Cancer
NYU Langone Presenter: Bhavana Pothuri, MD
Time: 9:00AM–12:00PM